Hormones and Agents Affecting Hormonal Mechanism : Anterior Pituitary and Hypothalanic Function
IHCG3 “HCG 3000IU injection” 3000IU/amp
IOVID1 “Ovidrel injection” 250 mcg/vial
適應症：
IOVID1：1.實施人工生殖協助技術(ART)，如體外受精(IVF)的超誘導排卵：投與OVIDREL可引起最終濾泡成熟與經刺激成長的濾泡黃體化；2.無排卵過少婦女的誘導排卵：投與OVIDREL可引起刺經刺激濾泡成長的無排卵過少婦女的排卵及黃體化。
IHCG3：無排卵症（無月經、無排卵週期不孕症）機能性子宮出血、黃體機能不全症、停留睪丸、造精機能不全男子不孕症、下垂體男子性腺機能不全（類宦官症）思春期遲發症、睪丸卵巢機能檢查、妊娠初期習慢性流產、妊娠初期之切迫性流產。
Usual dose:
250 mcg r-hCG is equivalent to 5000 U of uninary hCG.
Ovulation induction, ART (IVF): SC, 250 mcg at the time 24-48 h after the last dose of FSH and HMG.
IM Prepubertal cryptorchidism in males 500-4,000 u 3 times/wk. Continue for 1-2 mth after testicular descent. Male infertility due to hypogonadotrophic hypogonadism 500-4,000 u 2-3 times/wk. Delayed puberty due to hypogonadism in males Initial: 500-1,500 u twice wkly. Anovulatory infertility 5,000-10,000 u as a single dose. May repeat inj (up to 5,000 u/inj) up to 3 times w/in the next 9 days.
Contraindication:
Precocious puberty, prostate cancer or other androgen-dependent cancer.
Precaution:
Discontinue if signs of precocious puberty occur, fluid retention.
Adverse effect:
Common: injection site pain, gynecomastia, precocious puberty, thromboembolic disorder, headache, irritability.